Apitegromab Preserves 55% More Lean Mass With Tirzepatide in 102-Patient Trial
Updated
Updated · The Guardian · Jun 8
Apitegromab Preserves 55% More Lean Mass With Tirzepatide in 102-Patient Trial
3 articles · Updated · The Guardian · Jun 8
Summary
A 24-week trial found apitegromab cut lean-mass loss to 1.6 kg from 3.5 kg in people taking tirzepatide, while overall weight loss stayed similar to placebo.
The Nature Medicine study randomized 102 participants equally between apitegromab and placebo; the muscle-preserving drug blocks myostatin, a protein that limits muscle growth.
That matters because GLP-1 weight-loss drugs can drive 25% to 40% of total weight loss from lean body mass, which is tied to strength, calorie burning and lower type 2 diabetes risk.
Side effects were similar and mostly mild, but outside experts said the company-funded study was small, short and mostly female, so larger and longer trials are needed to confirm safety and functional benefit.
As drugs target 'Ozempic butt,' is high-quality weight loss becoming a luxury only the wealthy can afford?
Will a pill to save muscle make GLP-1 users abandon the essential lifestyle changes needed for long-term health?
What are the hidden long-term health risks of blocking a fundamental muscle-regulating protein like myostatin?
Preserving Muscle During Weight Loss: How Myostatin Inhibitors Like Apitegromab Enhance GLP-1 Therapy for Quality Obesity Treatment
Overview
GLP-1 receptor agonists have transformed obesity treatment by helping people lose weight, but they often cause a significant loss of lean muscle mass, which can harm health and reduce the quality of weight loss. This problem has led to the search for complementary treatments that can protect muscle while still reducing fat. Scholar Rock’s apitegromab, a selective myostatin inhibitor, addresses this issue. In the EMBRAZE Phase 2 trial, apitegromab showed it could help preserve muscle mass when used with GLP-1 therapies, offering a new approach to healthier, higher-quality weight loss for patients.